Dr. AbdelBaki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Childrens Pl
# Div
Saint Louis, MO 63110Phone+1 314-454-6018Fax+1 844-621-4392
Summary
- Dr. Mohamed Shebl Abdelbaki is the Director of the Pediatric Neuro-Oncology Program and the Clinical Research Office (CRO) for the Pediatric Hematology, Oncology and Bone Marrow Transplant Division at St. Louis Children's Hospital, and an Associate Professor of Pediatrics at Washington University School of Medicine in St. Louis – Missouri (USA). He is a member of the Central Nervous System (CNS) Committee at the Children’s Oncology Group (COG), and the study chair of the CNS Germinoma trial (ACNS2321) as well as a study committee member for the CNS non-germinomatous germ cell tumor clinical trial (ACNS2021). Additionally, he is the institutional Principal Investigator for both the COllaborative Network for NEuro-oncology Clinical Trials (CONNECT) consortium as well as the Pediatric Neuro-Oncology consortium (PNOC) – where he leads several clinical trials in pediatric brain tumors and also serves as a member of the scientific committee and the Chair of the Germ Cell Tumor Working Group.
Education & Training
- Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2009 - 2012
- Albany Medical CenterResidency, Pediatrics, 2006 - 2009
- Cairo University School of MedicineClass of 2002
Certifications & Licensure
- MO State Medical License 2020 - 2026
- OH State Medical License 2015 - 2021
- PA State Medical License 2011 - 2014
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Partners in Care, Partners in Hope Family Centered Care Award Nationwide Children's Hospital, 2016
Clinical Trials
- Phase 1 Study of Locoregional Injections of Ex Vivo Expanded Natural Killer Cells Start of enrollment: 2025 Apr 01
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors Start of enrollment: 2021 Dec 03
Roles: Principal Investigator
- REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Roles: Contact
- Join now to see all
Publications & Presentations
PubMed
- Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma.Erin E Crotty, Aimee A Sato, Mohamed S Abdelbaki
Frontiers in Oncology. 2025-01-01 - Pediatric Suprasellar Tumors: Unveiling the Mysteries of Craniopharyngioma and Germ Cell Tumors-Insights From Diagnosis to Advanced Therapeutics.Margaret Shatara, Mohamed S Abdelbaki
Pediatric Neurology. 2025-01-01 - 2 citationsRhabdoid tumor predisposition syndrome: A historical review of treatments and outcomes for associated pediatric malignancies.Sarah Andres, Karen Huang, Margaret Shatara, Mohamed S Abdelbaki, Mark Ranalli
Pediatric Blood & Cancer. 2024-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: